KAMURA Evidence Intelligence
Evidence Feed
Latest studies, regulatory changes, and safety alerts — curated for clinicians and informed consumers
FDA warns of contaminated research-grade peptides in grey market
FDA issued a safety alert after testing revealed that 23% of research-grade BPC-157 and TB-500 samples purchased online contained bacterial endotoxins exceeding safe limits. The agency emphasized the importance of pharmaceutical-grade sourcing.
Source: FDA Safety Communication
UAE MOHAP expands compounding pharmacy regulations for peptides
MOHAP issued updated guidance clarifying the legal pathway for physician-prescribed, pharmacy-compounded peptide therapy in the UAE. The new framework aligns with GMP standards and requires Certificate of Analysis documentation.
Source: MOHAP
FDA reclassifies 14 peptides back to Category 1
HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of the 19 restricted peptides will be reclassified back to Category 1, restoring the legal pathway for licensed compounding pharmacies. This is the biggest regulatory shift in peptide access in years.
Source: HHS Official Announcement
First controlled human trial for BPC-157 in tendon repair published
A 12-week randomized controlled trial (n=120) demonstrated that BPC-157 accelerated Achilles tendon healing by 40% compared to placebo, with no significant adverse events. The study was published in the Journal of Orthopaedic Research.
Source: Journal of Orthopaedic Research, 2026
MOTS-c confirmed as exercise mimetic in human trial
A Phase 2 trial showed that MOTS-c improved insulin sensitivity and mitochondrial function in sedentary adults comparable to 8 weeks of moderate exercise. The peptide activated AMPK and enhanced fatty acid oxidation.
Source: Cell Metabolism, 2025
Abu Dhabi launches world's first longevity medicine licensing framework
Abu Dhabi's Department of Health introduced the world's first licensing framework for Healthy Longevity Medicine Centres (HLMCs). IHLAD became the first government-licensed longevity centre, offering AI-driven personalised peptide protocols.
Source: DOH Abu Dhabi
GHK-Cu shows 35% hair density increase in clinical trial
A randomized controlled trial comparing topical GHK-Cu to minoxidil found comparable hair regrowth (35% density increase) with fewer side effects. The peptide's mechanism works through Wnt/β-catenin pathway activation in hair follicle stem cells.
Source: Dermatologic Therapy, 2025
Thymosin Alpha-1 reduces hepatitis B viral load by 60% in Phase 3 trial
A large Phase 3 trial across 15 sites confirmed Thymosin Alpha-1's efficacy in chronic hepatitis B, reducing viral load by 60% and achieving seroconversion in 38% of patients at 52 weeks.
Source: Hepatology, 2025